CagriSema (Cagrilintide + Semaglutide)

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: investigational combination not FDA approved

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

• Personal or family history of Medullary Thyroid Carcinoma (MTC): the GLP-1 receptor agonist (Semaglutide) component carries a class-level FDA boxed warning for thyroid C-cell tumor risk based on rodent carcinogenicity data; MTC risk in humans is not established but the warning applies to all GLP-1RAs; personal or family history of MTC is an absolute contraindication. Limited / unverified
• Multiple Endocrine Neoplasia Type 2 (MEN2): MEN2 patients have a near-universal predisposition to MTC; the GLP-1RA component's thyroid C-cell stimulation is absolutely contraindicated in this genetic syndrome. Limited / unverified
• Pre-existing gastroparesis (any severity): both Semaglutide (via GLP-1R-mediated vagal suppression of gastric motility) and Cagrilintide (via amylin receptor-mediated area postrema and vagal gastric emptying delay) independently inhibit gastric emptying; in subjects with pre-existing gastroparesis, the combined gastric motility inhibition of CagriSema can produce severe gastric stasis, vomiting, aspiration, and medically significant deterioration of gastric function; absolute contraindication. Limited / unverified
• Active pancreatitis or history of pancreatitis: GLP-1 receptor agonists carry a class-level association with acute pancreatitis; history of pancreatitis is a relative-to-absolute contraindication depending on clinical context. Limited / unverified
• Type 1 diabetes without insulin coverage: the GLP-1RA component suppresses glucagon and slows gastric emptying, but does not replace insulin; T1DM subjects using CagriSema without adequate insulin therapy face severe hypoglycemia risk. Limited / unverified
• Concurrent use of other GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide): CagriSema already contains a full-dose GLP-1RA; adding a second GLP-1RA produces receptor saturation without additional benefit and magnifies all GLP-1-mediated adverse effects. Limited / unverified
• Concurrent use of tirzepatide, retatrutide, mazdutide, or survodutide: these compounds contain GLP-1R agonist components; combining with CagriSema produces redundant GLP-1R loading, significantly elevated gastroparesis risk, and additive nausea/vomiting without therapeutic benefit beyond CagriSema alone. Limited / unverified
• Concurrent cagrilintide (standalone): CagriSema already contains the full amylin receptor agonist component; adding standalone Cagrilintide produces amylin receptor saturation and magnifies all amylin-mediated adverse effects. Limited / unverified
• Severe renal impairment (eGFR <15 ml/min): the pharmacokinetics of both components in severe renal failure require dose adjustment or avoidance; GLP-1RA-associated nausea and dehydration in subjects with severely compromised renal function carries acute kidney injury risk. Limited / unverified
• Severe hepatic impairment (Child-Pugh C): semaglutide pharmacokinetics are not significantly altered by liver disease but severe hepatic impairment context warrants medical supervision. Limited / unverified
• Known hypersensitivity to semaglutide, cagrilintide, or any formulation excipients. Limited / unverified
• Pregnancy and breastfeeding: weight loss pharmacotherapy is contraindicated during pregnancy; the fetal effects of GLP-1RA and amylin agonist exposure are not established and significant weight loss during pregnancy carries fetal risk. Limited / unverified
• Concurrent insulin secretagogues (sulfonylureas, meglitinides) without dose adjustment: GLP-1RA-mediated enhancement of glucose-dependent insulin secretion combined with insulin secretagogues increases hypoglycemia risk requiring dose adjustment of the secretagogue. Limited / unverified
• Pre-surgical procedures requiring general anesthesia: the profound gastric emptying delay of CagriSema increases aspiration risk under general anesthesia; a minimum 7-day (ideally 14-day) cessation period before elective general anesthesia is required. Limited / unverified
• Adipotide: concurrent use of a proapoptotic adipose-targeting compound adds significant metabolic stress to the already profound caloric restriction and adipose loss of CagriSema; combined use without medical supervision carries risks of excessive fat mass depletion, electrolyte imbalance, and renal stress. Limited / unverified

Side effects (limited evidence)

• Severe delayed gastric emptying (gastroparesis-like syndrome): the most clinically significant adverse effect unique to CagriSema versus semaglutide monotherapy; the additive GLP-1R and amylin receptor gastric motility inhibition produces markedly more pronounced and prolonged gastric stasis than semaglutide alone; manifests as persistent post-meal fullness, early satiety, nausea for 24-48 hours post-injection, and in severe cases, inability to tolerate solid food for days following the weekly dose. Limited / unverified
• Nausea and vomiting: most severe in the first 4-8 weeks of each dose escalation step; the incidence and severity exceed semaglutide monotherapy due to the additive amylin receptor contribution to nausea signaling in the area postrema; typically improves within 2-4 weeks at each dose level. Limited / unverified
• Fatigue and asthenia: commonly reported during dose escalation; related to caloric restriction, altered nutrient absorption timing, and possible direct central effects of amylin receptor agonism. Limited / unverified
• Hypoglycemia (in the context of severe caloric restriction): CagriSema itself does not directly cause hypoglycemia in non-diabetic subjects as GLP-1 receptor agonism is glucose-dependent; however, the profound appetite suppression and caloric restriction achieved on CagriSema can drive blood glucose to low-normal or mildly hypoglycemic values in subjects who do not compensate with adequate carbohydrate intake; more significant in subjects with concurrent insulin secretagogue use. Limited / unverified
• Constipation: common; secondary to the profound slowing of gastrointestinal motility from both components; can be severe and require active management (osmotic laxatives, adequate hydration, fiber). Limited / unverified
• Diarrhea: paradoxically, some subjects experience diarrhea alternating with constipation as gastric motility patterns change during dose escalation. Limited / unverified
• Injection site reactions: subcutaneous injection site erythema, bruising, or nodule formation; more common than semaglutide monotherapy possibly related to the higher concentration of the co-formulated product. Limited / unverified
• Muscle mass loss (lean body mass depletion): the most clinically important body composition concern; the profound caloric deficit produced by CagriSema, if not actively managed with adequate protein intake and resistance exercise, produces significant skeletal muscle loss alongside fat loss; anabolic support compounds (GH secretagogues, IGF-1 axis compounds) are frequently co-administered to mitigate this effect. Limited / unverified
• Hair thinning (telogen effluvium): commonly reported during rapid weight loss periods; secondary to the metabolic stress of significant caloric restriction rather than a direct pharmacological effect of either compound; typically reversible. Limited / unverified
• Elevated resting heart rate: a class-level effect of GLP-1 receptor agonists; Semaglutide increases mean resting heart rate by 2-4 BPM; typically not clinically significant but warrants monitoring in subjects with pre-existing tachyarrhythmias. Limited / unverified
• Gallstones and biliary disease: GLP-1 receptor agonists increase gallstone formation risk related to rapid weight loss and altered gallbladder motility; risk is amplified with the accelerated weight loss of CagriSema versus semaglutide monotherapy. Limited / unverified
• Acute pancreatitis (rare): the class-level GLP-1RA pancreatitis association; subjects should be aware of persistent severe abdominal pain as a warning sign requiring immediate medical evaluation. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/40544433/
• https://www.nejm.org/doi/abs/10.1056/NEJMoa2502082